These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32832297)

  • 1. Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab.
    Saleem T; Qurashi H; Jamali M; Chan Gomez J; Kanderi T
    Cureus; 2020 Jul; 12(7):e9300. PubMed ID: 32832297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
    Jin R; Mahtani RL; Accortt N; Lawrence T; Sandschafer D; Loaiza-Bonilla A
    Ther Adv Med Oncol; 2021; 13():17588359211041961. PubMed ID: 35003333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
    Xue X; Qian J
    Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinical Review of Biosimilars Approved in Oncology.
    Ngo D; Chen J
    Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb.
    Booth JP; Pilz J
    Hosp Pharm; 2022 Aug; 57(4):455-461. PubMed ID: 35898250
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.
    Safdar A; Butt MH; Ahmad A; Zaman M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1195-1204. PubMed ID: 34096401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars.
    Uifălean A; Ilieş M; Nicoară R; Rus LM; Hegheş SC; Iuga CA
    Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30257528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
    Xue X; Truong B; Qian J
    Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database.
    Nikitina V; Santi Laurini G; Montanaro N; Motola D
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
    Busse A; Lüftner D
    Breast Care (Basel); 2019 Mar; 14(1):10-16. PubMed ID: 31019437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody biosimilars for cancer treatment.
    Broer LN; Knapen DG; de Groot DA; Mol PGM; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
    iScience; 2024 Jun; 27(6):110115. PubMed ID: 38974466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
    Zhang C; Friedman S; Mruthyunjaya P; Parikh R
    Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.